TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 93 filers reported holding TCR2 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $119,000 | -93.0% | 43,123 | -88.2% | 0.00% | -100.0% |
| Q4 2021 | $1,700,000 | +171.1% | 364,726 | +395.0% | 0.00% | – |
| Q3 2021 | $627,000 | -32.9% | 73,686 | +29.3% | 0.00% | -100.0% |
| Q2 2021 | $935,000 | -24.7% | 56,990 | +1.4% | 0.00% | 0.0% |
| Q1 2021 | $1,241,000 | -29.6% | 56,200 | -1.3% | 0.00% | 0.0% |
| Q4 2020 | $1,762,000 | +52.3% | 56,952 | +0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,157,000 | +45.9% | 56,947 | +10.3% | 0.00% | 0.0% |
| Q2 2020 | $793,000 | +162.6% | 51,629 | +32.4% | 0.00% | – |
| Q1 2020 | $302,000 | -35.5% | 39,006 | +19.1% | 0.00% | – |
| Q4 2019 | $468,000 | -4.9% | 32,745 | +0.1% | 0.00% | – |
| Q3 2019 | $492,000 | -1.8% | 32,720 | -6.6% | 0.00% | – |
| Q2 2019 | $501,000 | +1.2% | 35,044 | +23.5% | 0.00% | – |
| Q1 2019 | $495,000 | – | 28,372 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |